Metabolomic profiling of the entire UK Biobank enables interpretation of familial hypercholesterolemia mutations and prediction of severe cardiovascular outcomes

Back

ESC Professional Premium Access

Metabolomic profiling of the entire UK Biobank enables interpretation of familial hypercholesterolemia mutations and prediction of severe cardiovascular outcomes

Session: Lipids as cardiovascular risk factors and treatment options

Topic: Lipids

Speaker: Doctor J. Barrett (Helsinki, FI)

Event: ESC Congress 2024

Congress Presentation

Add to my library

About the speaker

Doctor Jeffrey Barrett

Helsinki (Finland)

0 follower

4 more presentations in this session

Intraindividual variability in lipoprotein(a): the value of a repeat measure for reclassifying individuals at intermediate-risk

Speaker: Doctor T. Harb (Baltimore, US)

Lipoprotein(a) metabolomic and proteomic features and atherosclerotic cardiovascular disease in young, asymptomatic adults

Speaker: Associate Professor S. Goonewardena (Ann Arbor, US)

Combination therapy with GalNAc-siRNA drugs targeting both PCSK9 and APOC3 resulted in enhanced lipid lowering in mice

Speaker: Doctor J. Wikstrom (SE)

Reduction of triglyceride-rich lipoproteins with retatrutide in type 2 diabetes may be explained by concurrent reduction in ANGPTL3/8 levels

Speaker: Doctor G. Ruotolo (Indianapolis, US)

Access the full session

Lipids as cardiovascular risk factors and treatment options

Speakers: Doctor J. Barrett, Doctor T. Harb, Associate Professor S. Goonewardena, Doctor J. Wikstrom, Doctor G. Ruotolo

Access

Video

About the event

ESC Congress 2024

30 August - 2 September 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources